Essex Bio-Technology (HKSE:01061) Earnings Power Value (EPV): HK$8.45 (As of Dec25)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01061 Essex Bio-Technology Ltd HKSE:01061
86 GF Score
Price HK$2.29
GF Value HK$3.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Essex Bio-Technology Earnings Power Value (EPV)?

Essex Bio-Technology HKSE:01061 +0.88% 86 Earnings Power Value (EPV) is HK$8.45 as of Dec25. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

As of Dec25, Essex Bio-Technology's earnings power value is HK$8.45. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is 72.9

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Essex Bio-Technology  (HKSE:01061) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Essex Bio-Technology Earnings Power Value (EPV) Related Terms


Essex Bio-Technology Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Essex Bio-Technology's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Essex Bio-Technology Earnings Power Value (EPV) Chart

Essex Bio-Technology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.94 4.63 5.68 6.54 8.45

Essex Bio-Technology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 6.54 0.00 8.45 0.00

HKSE:01061 vs ZTS: Earnings Power Value (EPV) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Essex Bio-Technology Earnings Power Value (EPV) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Essex Bio-Technology's Earnings Power Value (EPV) falls into.


HKSE:01061
86GF Score
Essex Bio-Technology Ltd HKSE:01061
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Essex Bio-Technology Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Essex Bio-Technology's "Earning Power" Calculation:

Average of Last 5 Years Last Year
Revenue 1,635
DDA 51
Operating Margin % 21.97
SGA * 25% 274
Tax Rate % 17.53
Maintenance Capex 135
Cash and Cash Equivalents 784
Short-Term Debt 69
Long-Term Debt 278
Shares Outstanding (Diluted) 567

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = 21.97%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = HK$1,635 Mil, Average Operating Margin = 21.97%, Average Adjusted SGA = 274,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 1,635 * 21.97% +274 = HK$633.737353768 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 17.53%, and "Normalized" EBIT = HK$633.737353768 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = 633.737353768 * ( 1 - 17.53% ) = HK$522.66854514662 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 51 * 0.5 * 17.53% = HK$4.43802135 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = 522.66854514662 + 4.43802135 = HK$527.10656649662 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Essex Bio-Technology's Average Maintenance CAPEX = HK$135 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Essex Bio-Technology's current cash and cash equivalent = HK$784 Mil.
Essex Bio-Technology's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 278 + 69 = HK$346.905 Mil.
Essex Bio-Technology's current Shares Outstanding (Diluted Average) = 567 Mil.

Essex Bio-Technology's Earnings Power Value (EPV) for Dec25 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( 527.10656649662 - 135)/ 9%+784-346.905 )/567
=8.45

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( 8.4488953181358-2.29 )/8.4488953181358
= 72.9%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of HK$8.45 mean?
Essex Bio-Technology (HKSE:01061) has a Earnings Power Value (EPV) of HK$8.45 as of Dec25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Essex Bio-Technology and its competitors.
Is Essex Bio-Technology's Earnings Power Value (EPV) too high?
Essex Bio-Technology's current Earnings Power Value (EPV) is HK$8.45. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Earnings Power Value (EPV) compare to ZTS?
Essex Bio-Technology's Earnings Power Value (EPV) of HK$8.45 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Drug Manufacturers company?
A good Earnings Power Value (EPV) depends on the Drug Manufacturers industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Essex Bio-Technology and its competitors. Essex Bio-Technology's current Earnings Power Value (EPV) is HK$8.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Earnings Power Value (EPV) is HK$8.45. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Earnings Power Value (EPV) is HK$8.45 as of Dec25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?

Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued. The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13. GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.

Key valuation signals for HKSE:01061:

  • Earnings Power Value (EPV): HK$8.45
  • GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
  • GF Score™: 86/100 with 3 warning signs

No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Essex Bio-Technology Business Description

Address No. 88, Keji 6th Road, Hi-Tech Zone, Guangdong, Zhuhai, CHN
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score

Get the complete analysis for HKSE:01061

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.29
Price
HK$3.13
GF Value